This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vivus Weight-Loss Pill Approved -- Maybe?

MOUNTAIN VIEW, Calif. ( TheStreet) -- U.S. regulators have apparently approved Vivus' (VVUS - Get Report) weight-loss pill Qsymia on Tuesday, which means obese Americans now have a choice in prescription diet pills.

A story touting Qsymia's approval was published prematurely by USA Today earlier today. The story, since removed from the newspaper's web site, quotes Vivus executives and doctors about Qsymia and its approval. Clearly, the reporter wrote the story under embargo with Vivus' cooperation but was not supposed to publish until after an official announcement from FDA that the weight-loss pill had been approved.

Neither Vivus nor officials from the U.S. Food and Drug Administration have made made any official comment.

Vivus shares are down 1% to $28.30 in recent trading, which has been volatile throughout the day.

So, FDA has now reportedly approved two new medicines to treat obesity in the past three weeks, ending a 13-year drought. The first pill, Arena Pharmaceuticals' (ARNA - Get Report) Belviq, was approved on June 27.

Approximately one-third of adult Americans are obese today, according to the Centers for Disease Control. Obesity is growing public health problem in the U.S., in part because people who carry unhealthy weight are at greater risk for heart disease, diabetes and other diseases.

Qsymia, formerly known as Qnexa, combines two currently approved drugs -- phentermine, a generic weight loss drug, and topiramate, used to treat epilepsy and migraines.

FDA reportedly approved Qsymia based on data from clinical trials showing the drug helps patients lose approximately 10% of their baseline weight after one year. Similarly, 60-75% of Qsymia-treated patients lost at least 5% of their body weight after one year.

Women who take Qsymia while pregnant are at risk for giving birth to children with birth defects. For this reason, FDA has reportedly placed warnings on Qsymia's label urging women to use birth control while taking the weight-loss drug.

Vivus will conduct a post-approval cardiovascular outcomes study of Qnexa in order to further demonstrate that long-term use of the drug doesn't increase the risk of heart-related side effects.

Qysmia reportedly received U.S. approval on its second attempt. FDA rejected the drug in 2010 due to safety concerns. A subsequent FDA advisory panel held in February voted 20-2 to recommend the drug's approval.

Arena shares were down 3% to $10.80 in recent trading. Shares of Orexigen Therapeutics (OREX - Get Report), developer of a third weight-loss pill still in a late-stage clinical trial, were down 3% to $7.17.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.72 0.00%
OREX $0.45 0.00%
VVUS $1.65 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs